{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:40:38Z","timestamp":1790221238970,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jconrel.2023.06.025","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T13:04:19Z","timestamp":1688562259000},"page":"316-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax\u00ae against COVID-19 in nonhuman primates"],"prefix":"10.1016","volume":"360","author":[{"given":"Parvin","family":"Zamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mashreghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahere","family":"Rezazade Bazaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Zargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahyar","family":"Dorrigiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asghar","family":"Abdoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Aminianfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Hatamipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Zarqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Behboodifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalda","family":"Samsami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeideh","family":"Khorshid Sokhangouy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Sefidbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuk","family":"Uskokovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mahdi","family":"Rezayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Mozaffari-Jovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.06.025_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41579-022-00711-2","article-title":"Author correction: characteristics of SARS-CoV-2 and COVID-19","volume":"20","author":"Hu","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0010","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1038\/s41586-020-2202-3","article-title":"Author correction: a new coronavirus associated with human respiratory disease in China","volume":"580","author":"Wu","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41426-018-0155-5","article-title":"Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats","volume":"7","author":"Hu","year":"2018","journal-title":"Emerg. Microbes. Infect."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101422","article-title":"The immunology of SARS-CoV-2 infections and vaccines","volume":"50","author":"Grigoryan","year":"2020","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0030","first-page":"261","article-title":"mRNA vaccines \u2013 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Publ. Group"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2020.01.008","article-title":"Recent advances in mRNA vaccine technology","volume":"65","author":"Pardi","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pbiomolbio.2023.02.004","article-title":"An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines","volume":"178","author":"Bayani","year":"2023","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13037-021-00291-9","article-title":"Review the safety of Covid-19 mRNA vaccines: a review","volume":"15","author":"Anand","year":"2021","journal-title":"Patient Saf. Surg."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21186582","article-title":"Mrna vaccine era\u2014mechanisms, drug platform and clinical prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0055","article-title":"Immune responses induced by mRNA vaccination in mice, monkeys and humans","volume":"9","author":"Cagigi","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0060","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","author":"Schlake","year":"2012","journal-title":"RNA Biol."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0065","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1021\/acs.molpharmaceut.8b01290","article-title":"Lipid nanoparticles for delivery of therapeutic RNA oligonucleotides","volume":"16","author":"Moss","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0070","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0075","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1038\/s41467-019-12275-6","article-title":"Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells","volume":"10","author":"Maugeri","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0080","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0090","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N 1 -methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0110","article-title":"Challenges of storage and stability of mRNA-based COVID-19 vaccines","volume":"9","author":"Uddin","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im0718bs66","article-title":"Measurement of cytokine production using whole blood","volume":"66","author":"Thurm","year":"2005","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1360","article-title":"Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate","volume":"11","author":"De Rosa","year":"2022","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2012.04.003","article-title":"Study designs for the nonclinical safety testing of new vaccine products","volume":"66","author":"Forster","year":"2012","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11120626","article-title":"Repeat-dose toxicity study using the AFPL1-conjugate nicotine vaccine in male Sprague Dawley rats","volume":"11","author":"Oliva","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0135","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.toxrep.2021.04.003","article-title":"Safety of COVID-19 vaccines administered in the EU: should we be concerned?","volume":"8","author":"Hern\u00e1ndez","year":"2021","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0140","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41392-021-00861-4","article-title":"Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"2021","key":"10.1016\/j.jconrel.2023.06.025_bb0145","first-page":"1372","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0150","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/all.15271","article-title":"Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization","author":"Cheng","year":"2022","journal-title":"Allergy."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.621","article-title":"Persistence of immune responses to the Sinopharm\/BBIBP-CorV vaccine","volume":"10","author":"Jeewandara","year":"2022","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0165","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2305","article-title":"Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: a preclinical study","volume":"32","author":"Abdoli","year":"2022","journal-title":"Rev. Med. Virol."},{"issue":"2020","key":"10.1016\/j.jconrel.2023.06.025_bb0170","first-page":"77","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0175","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0180","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet."},{"issue":"2020","key":"10.1016\/j.jconrel.2023.06.025_bb0185","first-page":"806","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0190","doi-asserted-by":"crossref","first-page":"100081","DOI":"10.1016\/j.xcrm.2020.100081","article-title":"Sars-Cov-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential","volume":"1","author":"Neidleman","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0195","doi-asserted-by":"crossref","first-page":"eabd2071","DOI":"10.1126\/sciimmunol.abd2071","article-title":"Phenotype and kinetics of SARS-CoV-2\u2013specific T cells in COVID-19 patients with acute respiratory distress syndrome","volume":"5","author":"Weiskopf","year":"2020","journal-title":"Sci. Immunol."},{"issue":"2020","key":"10.1016\/j.jconrel.2023.06.025_bb0200","first-page":"945","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0205","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2021.01.055","article-title":"Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"39","author":"Munoz","year":"2021","journal-title":"Vaccine."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0210","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0215","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01987-21","article-title":"Antibody-dependent enhancement of SARS-CoV-2 infection is mediated by the IgG receptors Fc\u03b3RIIA and Fc\u03b3RIIIA but does not contribute to aberrant cytokine production by macrophages","volume":"12","author":"Maemura","year":"2021","journal-title":"MBio."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0220","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-023-04555-1","article-title":"Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals","volume":"6","author":"Connors","year":"2023","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.06.025_bb0230","first-page":"1","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0235","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/22221751.2020.1852059","article-title":"Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models","volume":"9","author":"Wang","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0240","series-title":"Comirnaty-Epar-Public-Assessment-Report","author":"EMA","year":"2020"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0245","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaa070","article-title":"N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells","volume":"48","author":"Parr","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.jconrel.2023.06.025_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0255","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.11.022","article-title":"Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines","volume":"353","author":"Kim","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0260","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/v15030668","article-title":"Research advances on the stability of mRNA vaccines","volume":"15","author":"Cheng","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0265","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105735","article-title":"Insights into the structural peculiarities of the N-terminal and receptor binding domains of the spike protein from the SARS-CoV-2 omicron variant","volume":"147","author":"Bayani","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0275","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab241","article-title":"Tracking the pipeline: immunoinformatics and the COVID-19 vaccine design","volume":"22","author":"Rezaei","year":"2021","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0280","doi-asserted-by":"crossref","unstructured":"Kizzmekia S. Corbett, Anne P. Werner, Sarah O\u2019 Connell, Matthew Gagne, Lilin Lai, Juan I. Moliva, Barbara Flynn, Angela Choi, Matthew Koch, Kathryn E. Foulds, Shayne F. Andrew, Dillon R. Flebbe, Evan Lamb, Saule T. Nurmukhambetova, Samantha J. Provost, Kevin W. Bock, Mahnaz Minai, Bianca M. Nagata, Alex Van Ry, Zackery Flinchbaugh, Timothy S. Johnston, Elham Bayat Mokhtari, Prakriti Mudvari, Amy R. Henry, Farida Laboune, Becky Chang, Maciel Porto, Jaclyn Wear, Gabriela S. Alvarado, Seyhan Boyoglu-Barnum, John-Paul M. Todd, Bridget Bart, Anthony Cook, Alan Dodson, Laurent Pessaint, Katelyn Steingrebe, Sayda Elbashir, Manjari Sriparna, Andrew Pekosz, Hanne Andersen, Kai Wu, Darin K. Edwards, Swagata Kar, Mark G. Lewis, Eli Boritz, Ian N. Moore, Andrea Carfi, Mehul S. Suthar, Adrian McDermott, Mario Roederer, Martha C. Nason, Nancy J. Sullivan, Daniel C. Douek, Barney S. Graham, and Robert A. Seder. Mrna-1273 Protects against Sars-Cov-2 Beta Infection in Nonhuman Primates. Nature Immunology, 22 (2021), 1306-15.","DOI":"10.1038\/s41590-021-01021-0"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0285","series-title":"Laboratory Biosafety Guidance Related to Coronavirus Disease 2019 (COVID-19): Interim Guidance, 12 February 2020","author":"Organization, W.H","year":"2020"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0290","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3201\/eid2606.200516","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States","volume":"26","author":"Harcourt","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic. Acids."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0300","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","article-title":"Impact of lipid nanoparticle size on mRNA vaccine immunogenicity","volume":"335","author":"Hassett","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2021.114259","article-title":"Expediting in vitro characterization of mRNA-based gene therapies via high-content fluorescent imaging","volume":"627","author":"Vigil","year":"2021","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0310","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0315","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2019.04.019","article-title":"MPL nano-liposomal vaccine containing P5 HER2\/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer","volume":"303","author":"Zamani","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.025_bb0320","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/01926233211072767","article-title":"Modeling SARS-CoV-2: comparative pathology in rhesus macaque and golden syrian hamster models","volume":"50","author":"Choudhary","year":"2022","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jconrel.2023.06.025_bb0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2020.01.010","article-title":"Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer","volume":"129","author":"Zamani","year":"2020","journal-title":"Eur. J. Cancer"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592300398X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592300398X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:48:11Z","timestamp":1759164491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592300398X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":65,"alternative-id":["S016836592300398X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.025","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax\u00ae against COVID-19 in nonhuman primates","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}